HB 1638 creates a new statutory subdivision in RSA 420-J governing health insurer step therapy protocols. The bill requires carriers and utilization review organizations to base step therapy clinical review criteria on evidence-based clinical practice guidelines, with defined standards for transparency, conflict-of-interest controls, public comment, and ongoing updates. If suitable guidelines do not exist, peer-reviewed publications may be used, and reviewers must consider atypical patient populations and diagnoses.
The bill also establishes a formal, accessible process for enrollees and prescribers to request a step therapy override exception. Carriers must grant an override in specified circumstances, including when the required drug is contraindicated, likely ineffective, previously failed, not medically necessary, or when the patient is stable on the prescribed drug; it also creates a specific basis for serious mental illness. The bill requires prompt decisions on urgent, non-urgent, and emergent requests, continuation of coverage while a request is pending, and an appeal right. In addition, it prohibits step therapy protocols for certain prescription drugs used to treat advanced, metastatic cancer and associated conditions when the drugs meet the bill’s criteria.
The bill’s impact on state law would be to add new consumer protections and utilization-review requirements for health insurance plans regulated under RSA 420-J. It would constrain how insurers use step therapy, require faster and more standardized exception handling, and potentially increase coverage of higher-cost medications. The fiscal note anticipates no direct state expenditure, but it says administrative burdens on carriers and increased utilization could raise premiums, which could in turn produce an indeterminable increase in insurance premium tax revenue and higher costs for counties and municipalities that purchase health coverage.
Overall, the bill appears to have a consumer- and patient-protection orientation, especially for people with serious illnesses, cancer, or mental health conditions. The fiscal analysis suggests the Insurance Department expects operational and cost impacts on carriers, but the bill text and available context do not show recorded committee debate or votes. As a result, there is no documented split in the provided materials, though the main policy tension is between improving access to medically necessary treatment and preserving insurers’ ability to use step therapy as a cost-management tool.
The principal point of contention is likely the tradeoff between patient access and insurance cost control. Supporters would view the bill as limiting harmful delays and ensuring medically necessary treatment is not blocked by rigid drug-sequencing rules, while opponents or cost-conscious stakeholders may object that the mandated exceptions, timelines, and cancer-related prohibitions reduce utilization-management flexibility and could increase premiums.
HB 1638 would amend RSA 420-J by adding a new step-therapy subdivision that regulates how health carriers and utilization review organizations may impose drug-sequencing requirements. It would require evidence-based clinical criteria, create a standardized override process, mandate response deadlines, and prohibit step therapy for certain advanced metastatic cancer drugs meeting specified conditions. The bill would affect insurers, utilization review organizations, prescribers, and covered persons, and could indirectly affect public employers and local governments that purchase health insurance through higher premiums.
The available materials suggest generally favorable policy intent toward patient access and medically necessary care, with the bill framed as a consumer protection measure. No committee transcript or vote record is provided, so there is no direct evidence of formal support or opposition in the legislative record here. The fiscal note, however, reflects caution about administrative burden and possible premium increases, indicating that cost concerns are the main countervailing sentiment.
The main contention is whether step therapy should be tightly constrained to protect patients from delays and failed treatments, or left more flexible as a cost-containment tool for insurers. Insurers and the Insurance Department are likely to focus on the added administrative requirements, shorter decision timelines, and potential premium effects, while patient advocates and prescribers would likely support the override rights, cancer-related prohibitions, and protections for serious mental illness and stable patients. The bill’s requirement that carriers grant coverage during pending reviews and its automatic approval if deadlines are missed may also be controversial.